Revolution Medicines (RVMD) Stock Price, News & Analysis

Revolution Medicines, Inc. (Nasdaq: RVMD) is a late-stage clinical oncology company focused on developing novel targeted therapies for patients with RAS-addicted cancers. According to the company’s public disclosures, its research and development pipeline centers on RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, a key driver of several major solid tumors, including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

The company is classified under Biological Product (except Diagnostic) Manufacturing within the Manufacturing sector and lists its common stock on The Nasdaq Stock Market LLC under the symbol RVMD. Warrants to purchase shares of common stock expiring in 2026 trade under the symbol RVMDW, as disclosed in its SEC filings.

Focus on RAS(ON) Inhibition

Revolution Medicines describes its core scientific approach as targeting the active, GTP-bound state of RAS proteins, referred to as RAS(ON). Its RAS(ON) inhibitor portfolio is designed to address multiple oncogenic RAS variants. The company’s R&D pipeline includes:

• Daraxonrasib (RMC-6236), an oral, direct RAS(ON) multi-selective inhibitor that targets oncogenic RAS mutations G12X, G13X and Q61X, which are common drivers of major cancers such as PDAC, NSCLC and CRC. Daraxonrasib is being evaluated in several global Phase 3 clinical trials, including RASolute 302 in previously treated metastatic PDAC, RASolve 301 in previously treated metastatic NSCLC, and additional Phase 3 trials in first-line metastatic and adjuvant resectable PDAC.
• Elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor studied in patients with KRAS G12C NSCLC, including those previously treated with a KRAS(OFF) G12C inhibitor. Clinical data reported by the company describe antitumor activity and a tolerability profile in heavily pretreated patients with advanced KRAS G12C solid tumors.
• Zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to zoldonrasib for adult patients with KRAS G12D-mutated locally advanced or metastatic NSCLC who have received prior anti-PD-1/PD-L1 therapy and platinum-based chemotherapy. Zoldonrasib is being evaluated as monotherapy and in combination regimens across multiple tumor types and treatment settings.
• RMC-5127, a RAS(ON) G12V-selective inhibitor that the company has identified as its next RAS(ON) inhibitor expected to enter clinical development, according to its public statements.

In addition to these clinical-stage candidates, Revolution Medicines highlights mutant-selective RAS(ON) inhibitors in earlier development, including RMC-0708 (Q61H) and RMC-8839 (G13C). These programs extend the company’s strategy of designing agents that selectively target specific RAS mutations.

Late-Stage Clinical Development in RAS-Driven Cancers

Revolution Medicines characterizes itself as a late-stage clinical oncology company. Its disclosures describe multiple ongoing and planned Phase 3 trials for daraxonrasib in PDAC and NSCLC. For PDAC, the company has reported:

• RASolute 302, a global Phase 3 trial of daraxonrasib in patients with previously treated metastatic PDAC.
• RASolute 303, a planned global, randomized Phase 3 trial in first-line metastatic PDAC evaluating daraxonrasib monotherapy and daraxonrasib plus gemcitabine/nab-paclitaxel (GnP) versus GnP alone.
• RASolute 304, a global, open-label Phase 3 trial in patients with resectable PDAC who have undergone surgery and perioperative chemotherapy, assessing whether daraxonrasib can improve disease-free survival compared with observation.

For NSCLC, the company has disclosed RASolve 301, a global Phase 3 study of daraxonrasib versus docetaxel in patients with previously treated RAS-mutant NSCLC, and has indicated plans for a registrational trial of daraxonrasib in first-line metastatic RAS-mutant NSCLC in combination with pembrolizumab and chemotherapy.

Regulatory Designations and FDA Interactions

Revolution Medicines’ public communications describe several FDA designations for its RAS(ON) inhibitors:

• Daraxonrasib has received Breakthrough Therapy Designation and Orphan Drug Designation in pancreatic cancer, as well as a Commissioner’s National Priority Voucher under the FDA’s pilot program.
• Zoldonrasib has been granted Breakthrough Therapy Designation for KRAS G12D-mutated locally advanced or metastatic NSCLC after prior anti-PD-1/PD-L1 therapy and platinum-based chemotherapy. The company notes that this is the first Breakthrough Therapy Designation for an investigational drug specifically targeting the KRAS G12D mutation in NSCLC and its third Breakthrough Therapy Designation across its RAS(ON) inhibitor portfolio.
• Elironrasib has received Breakthrough Therapy Designation for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.

These designations, as described by the company, are intended to facilitate the development and review of investigational medicines that address serious conditions and unmet medical needs, based on preliminary clinical evidence.

Pipeline Strategy and Collaborations

Revolution Medicines’ disclosures emphasize a pipeline strategy built around both multi-selective and mutant-selective RAS(ON) inhibitors, including potential doublet combinations. The company has reported preclinical data supporting a combination of zoldonrasib and daraxonrasib in models of KRAS G12D PDAC, describing this as a RAS(ON) inhibitor doublet approach. It is also exploring combinations of its RAS(ON) inhibitors with other targeted agents through collaborations, including work with partners on combinations involving a PRMT5 inhibitor and a bi-specific PD-1/VEGF inhibitor, as described in its news releases.

From a financing perspective, Revolution Medicines has entered into a Royalty Purchase Agreement with Royalty Pharma and a related loan agreement, as detailed in its SEC filings. Under the Royalty Purchase Agreement, Royalty Pharma purchased rights to tiered revenue payments on potential future net product sales of daraxonrasib and, under specified conditions, zoldonrasib. The loan facility provides for multiple tranches of term loans contingent on regulatory approvals and sales milestones related to daraxonrasib and potential future performance of the company’s products.

Trading Information and Corporate Status

SEC filings identify Revolution Medicines, Inc. as the registrant with common stock listed on The Nasdaq Stock Market LLC under the symbol RVMD and warrants to purchase 0.1112 shares of common stock expiring in 2026 listed under RVMDW. The filings describe the company as a reporting issuer under the Securities Exchange Act of 1934 and do not indicate delisting, deregistration, or bankruptcy events in the provided materials.